T cell receptors that specifically recognize hAFP.sub.158 and methods of their use are provided.

Provided herein are methods of treating cancer by activating resident memory T cells using one or more antigenic peptides.

The invention is a simplified model on kidney rejection in animals and its setting approach. The method involves isolating dendritic cells from male mice and isolating T cells from female mice and then using the naive T cells in vitro to culture concurrently with male dendritic cells. Those activated T cells from female origin were injected into renal cortex in male mice for the purpose of attacking renal cortex. The animal model simulates the renal transplant rejection method to enable effective induction of renal transplant immune reaction.

An industrial preparation of natural killer cells (NKs) is produced by: using umbilical cord blood and peripheral blood from legitimate sources as raw materials, obtaining stem cells by a method for extracting and separating karyocytes, or using FICOLL? or PERCOLL? density gradient media centrifugation to isolate and screen out karyocytes; diluting the above-mentioned karyocytes with cell culture medium, adding interferon, interleukin, CD3 antibody, and human albumin, loading them together into a bioreactor for perfusion culture, and then performing multiplication culture; the passage number of natural killer cells from multiplication culture is no less than 8, and the culture time is no less than 4 weeks; the markers of the natural killer cells obtained after the multiplication culture are CD3.sup.?\CD56.sup.+, CD16.sup.+, CD57.sup.+, and CD8.sup.+, wherein CD16.sup.+/CD56.sup.+?15%, CD3.sup.?/CD56.sup.+?50%, and CD8.sup.+/CD57.sup.+?8%; then preparing an injection with a certain concentration using the cell suspension obtained by above-mentioned method.

Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.

An improved method for preparing T cell populations expressing a chimeric antigen receptor is described.

Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells.

The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Provided are chimeric receptors for engineering cells for adoptive therapy, including T cells, and the genetically engineered cells. In some aspects, also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects. In some embodiments, the cells, such as T cells, contain genetically engineered antigen receptors that specifically bind to antigens, such as a chimeric antigen receptor (CAR), and which contain an intracellular signaling domain capable of inducing TRAF6-mediated signaling. In some embodiments, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence.

The invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. The invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture platforms and methods disclosed herein, which enable feed-free, monolayer culturing and in the absence of EB formation. Specifically, pluripotent stem cell-derived hematopoietic cell of this invention include, and not limited to, iHSC, definitive hemogenic endothelium, hematopoietic multipotent progenitors, T cell progenitors, NK cell progenitors, T cells, NK cells, NKT cells and B cells.